Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease
1. Introduction - p. page_1 2. β-Blockers - p. page_1 3. Summary - p. page_37 4. Nitrates and Newer (or Nontraditional) Antianginals - p. page_39 5. Calcium Channel Blockers - p. page_57 6. Summary - p. page_89 7. Summary - p. page_94 8. 2: Antihypertensive Therapies - p. page_97 9. 3: Heart Failure - p. page_147 10. 4: Drugs for Diabetes - p. page_231 11. 5: Drugs for Obesity - p. page_277 12. 6: Lipid-Modifying Drugs - p. page_299 13. 7: Drugs Targeting Inflammation - p. page_359 14. 8: Antithrombotic Drugs - p. page_387 15. Introduction - p. page_387 16. Thrombosis - p. page_388 17. Emerging Construct and Future Targets for Antithrombotic Therapy - p. page_398 18. Cardiovascular Drug Therapy - p. page_400 19. Platelet-Directed Therapies - p. page_400 20. Platelet P2Y12 Receptor Antagonists - p. page_415 21. Periprocedural Management of Antiplatelet Therapy - p. page_437 22. Intravenous Platelet GPIIb/IIIa Receptor Antagonists - p. page_446 23. Summary of Recommendations in Patients With ACS - p. page_458 24. Anticoagulants - p. page_459 25. Parenteral Anticoagulant Drugs - p. page_465 26. Direct Thrombin Inhibitors - p. page_465 27. Direct FXa Inhibitors - p. page_466 28. Indirect, Selective FXa Inhibitors - p. page_472 29. Direct Thrombin Inhibitors - p. page_480 30. Argatroban - p. page_484 31. Reversal and Replacement Therapy for Parenteral Anticoagulants - p. page_487 32. Oral Anticoagulant Drugs - p. page_487 33. Pharmacokinetics and Drug Disposition - p. page_487 34. Oral Direct Thrombin Inhibitors - p. page_495 35. Vitamin K Antagonists - p. page_513 36. Reversal and Replacement of Direct Oral Anticoagulant Drugs - p. page_519 37. Achieving Good Hemostasis - p. page_523 38. Conclusions - p. page_527 39. 9: Antiarrhythmic Drugs - p. page_533 40. 10: Vascular Medicine Drugs - p. page_593 41. 11: Drugs for Pulmonary Hypertension - p. page_623 42. Index - p. page_657
Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease
1. Introduction - p. page_1 2. β-Blockers - p. page_1 3. Summary - p. page_37 4. Nitrates and Newer (or Nontraditional) Antianginals - p. page_39 5. Calcium Channel Blockers - p. page_57 6. Summary - p. page_89 7. Summary - p. page_94 8. 2: Antihypertensive Therapies - p. page_97 9. 3: Heart Failure - p. page_147 10. 4: Drugs for Diabetes - p. page_231 11. 5: Drugs for Obesity - p. page_277 12. 6: Lipid-Modifying Drugs - p. page_299 13. 7: Drugs Targeting Inflammation - p. page_359 14. 8: Antithrombotic Drugs - p. page_387 15. Introduction - p. page_387 16. Thrombosis - p. page_388 17. Emerging Construct and Future Targets for Antithrombotic Therapy - p. page_398 18. Cardiovascular Drug Therapy - p. page_400 19. Platelet-Directed Therapies - p. page_400 20. Platelet P2Y12 Receptor Antagonists - p. page_415 21. Periprocedural Management of Antiplatelet Therapy - p. page_437 22. Intravenous Platelet GPIIb/IIIa Receptor Antagonists - p. page_446 23. Summary of Recommendations in Patients With ACS - p. page_458 24. Anticoagulants - p. page_459 25. Parenteral Anticoagulant Drugs - p. page_465 26. Direct Thrombin Inhibitors - p. page_465 27. Direct FXa Inhibitors - p. page_466 28. Indirect, Selective FXa Inhibitors - p. page_472 29. Direct Thrombin Inhibitors - p. page_480 30. Argatroban - p. page_484 31. Reversal and Replacement Therapy for Parenteral Anticoagulants - p. page_487 32. Oral Anticoagulant Drugs - p. page_487 33. Pharmacokinetics and Drug Disposition - p. page_487 34. Oral Direct Thrombin Inhibitors - p. page_495 35. Vitamin K Antagonists - p. page_513 36. Reversal and Replacement of Direct Oral Anticoagulant Drugs - p. page_519 37. Achieving Good Hemostasis - p. page_523 38. Conclusions - p. page_527 39. 9: Antiarrhythmic Drugs - p. page_533 40. 10: Vascular Medicine Drugs - p. page_593 41. 11: Drugs for Pulmonary Hypertension - p. page_623 42. Index - p. page_657
